The price of Outlook Therapeutics Inc. (NASDAQ:OTLK) shares last traded on Wall Street rose 15.74% to $1.25.
Based on available information, 4 analysts follow Outlook Therapeutics Inc. (NASDAQ:OTLK). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $5.00, we find $6.00. Given the previous closing price of $1.08, this indicates a potential upside of 455.56 percent. OTLK stock price is now 21.57% away from the 50-day moving average and 1.12% away from the 200-day moving average. The market capitalization of the company currently stands at $279.88M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
Among analysts, 0 rate the stock a hold while 4 rate it a buy. Brokers who have rated the stock have averaged $6.75 as their price target over the next twelve months.
With the price target of $7, BTIG Research recently initiated with Buy rating for Outlook Therapeutics Inc. (NASDAQ: OTLK). On September 13, 2022, Chardan Capital Markets recently initiated its ‘Buy’ rating on the stock quoting a target price of $10, while ‘Ladenburg Thalmann’ rates the stock as ‘Buy’.
In other news, Sukhtian Faisal Ghiath, Director bought 30,000 shares of the company’s stock on Oct 07. The stock was bought for $38,700 at an average price of $1.29. Upon completion of the transaction, the Director now directly owns 68,000 shares in the company, valued at $85000.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 07, Director Haddadin Yezan Munther bought 3,600 shares of the business’s stock. A total of $4,572 was incurred on buying the stock at an average price of $1.27. This leaves the insider owning 63,343 shares of the company worth $79178.75. Insiders disposed of 30,482,529 shares of company stock worth roughly $38.1 million over the past 1 year. A total of 0.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in OTLK stock. A new stake in Outlook Therapeutics Inc. shares was purchased by SUSQUEHANNA INTERNATIONAL GROUP, LLP during the first quarter worth $45,000. SQUAREPOINT OPS LLC invested $40,000 in shares of OTLK during the first quarter. In the first quarter, AMALGAMATED FINANCIAL CORP. acquired a new stake in Outlook Therapeutics Inc. valued at approximately $18,000. D. E. SHAW & CO., INC. acquired a new stake in OTLK for approximately $13,000. JANE STREET GROUP, LLC purchased a new stake in OTLK valued at around $13,000 in the second quarter. In total, there are 103 active investors with 10.70% ownership of the company’s stock.
A candlestick chart of Outlook Therapeutics Inc. (NASDAQ: OTLK) showed a price of $1.0800 on Thursday morning. During the past 12 months, Outlook Therapeutics Inc. has had a low of $0.68 and a high of $2.12. As of last week, the company has a debt-to-equity ratio of 1.25, a current ratio of 1.40, and a quick ratio of 1.40. The fifty day moving average price for OTLK is $1.0283 and a two-hundred day moving average price translates $1.2362 for the stock.
The latest earnings results from Outlook Therapeutics Inc. (NASDAQ: OTLK) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.08, missing analysts’ expectations of -$0.07 by -0.01. This compares to -$0.07 EPS in the same period last year. The company reported revenue of $13.99 million for the quarter, compared to $13.44 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 4.11 percent.
Outlook Therapeutics Inc.(OTLK) Company Profile
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
